Roth Capital Starts Biotie Therapies (BITI) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
JMP Securities Starts Biotie Therapies (BITI) at Market Outperform
July 6, 2015 8:02 AM EDTJMP Securities initiated coverage on Biotie Therapies (NASDAQ: BITI) with a Market Outperform rating and a price target of $32.00.
For an analyst ratings summary and ratings history on Biotie Therapies click here. For more ratings news on Biotie Therapies click here.
Shares of Biotie Therapies closed at $18.39 yesterday.
... MoreStifel Starts Biotie Therapies (BITI) at Buy
July 6, 2015 8:01 AM EDTStifel initiated coverage on Biotie Therapies (NASDAQ: BITI) with a Buy rating and a price target of $30.00.
For an analyst ratings summary and ratings history on Biotie Therapies click here. For more ratings news on Biotie Therapies click here.
Shares of Biotie Therapies closed at $18.39 yesterday.
... MoreUPDATE: RBC Capital Starts Biotie Therapies (BITI) at Outperform
July 6, 2015 8:01 AM EDT(Updated - July 6, 2015 8:29 AM EDT)
RBC Capital initiated coverage on Biotie Therapies (NASDAQ: BITI) with an Outperform rating and a price target of $35. Analyst Simos Simeonidis is bullish on Tozadenant and thinks it could be the first Parkinsons Disease drug approved with a new mechanism in a generation.
"Tozadenant, Biotie's A2A receptor antagonist, is entering a Phase III... More
